Impulse control disorders in patients with Parkinson's disease

Acta Neurologica Belgica

Volumn 111, Issue 1, 2011, Pages 3-9

  Gescheidt, Tomáš ^a   Bareš, Martin ^a,b  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b Movement Disorders Centre Brno   (Czech Republic)

Author keywords

Dopamine dysregulation syndrome; Dopaminergic agonists; Hypersexuality; Impulse control disorders; Parkinson's disease; Pathological gambling; Punding

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT;

CLINICAL PRACTICE; COMPULSION; DOPAMINERGIC TRANSMISSION; EATING; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; REVIEW; RISK FACTOR; SHOPPING; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE;

GAMBLING; HUMANS; IMPULSE CONTROL DISORDERS; PARKINSON DISEASE; QUALITY OF LIFE; RISK FACTORS;

EID: 79955864542     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive Behaviors in Parkinson's Disease. Mov Disord. 2009; 24(11): 1561-1570.
2. Gescheidt T, Bareš M. Pathological gambling in patients with Parkinson's disease. Neurol pro praxi. 2009; 10(2): 107-110.
3. Weintraub D, Hoops S, shea JA, Lyons KE, Pahwa R. et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord. 2009; 24(10): 1461-1467.
4. Voon V, Fox SH. Medication-related impulse control and Repetitive Behaviors in Parkinson Disease. Arch Neurol. 2007; 64: 1089-1096.
5. Molina JA, Sáinz-Artiga MJ, Fraile A, Jiménez Jiménez FJ, Villanueva C. et al. Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment? Mov Disord. 2000; 5: 869-872.
6. Seedat S, Keller S, Niehaus DJH, stein DJ. Pathological Gambling Behaviour: Emergence secondary to Treatment of Parkinson's Disease with Dopaminergic Agents. Depression and Anxiety. 2000; 11: 185-186.
7. Avanzi M, Uber E, Bonfà F. Pahological gambling in two patiens on dopamine replacement therapy for Parkinson's Disease. Neurol sci. 2004; 25: 98-101.
8. Voon V, Hassan K, Zurowski M, Surf-Caning S, de Souza M. et al. Prospective prevalence of pathological gambling and medication association in Parkinsons disease. Neurology. 2006; 66: 1750-1752.
9. Singh A, Kandimala G, Dewey RB, O'Suilleabhain P. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patiens taking dopamine agonists. J Clin Neurosci. 2007; 14: 178-1181.
10. Voon V, Thomsen T, Miyasaki JM, de Souza M, Shafro A. et al. Factors Associated With Dopaminergic Drug-Related Pathological Gambling in Parkinson Disease. Arch Neurol. 2007; 64: 212-216.
11. Zand R. Is Dopamine Agonist Therapy Associated with Developing Pathological Gambling in Parkinson's Disease Pacients? Eur Neurology. 2008; 59: 183-186.
12. Johnson EE, Hamer R, Nora RM, Tan B, Eisenstein A. et al. The lie/bet questionare for screening pathological gamblers. Psychologial reports. 1997; 80: 83-88.
13. Weintraub D, Koestler J, Potenza MN, Siderowf AD, Stacy M, Voon V. et al. Dopaminergic therapy and impulse control disorders in Parkinson's diseaese: to Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010; 67(5): 589-595.
14. Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T. et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson's disease. Neurology. 2006; 67: 1254-1257.
15. Kaňovský P, Bareš M, Pohanka M, Rektor I. Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson's disease. J Neurol. 2002; 249: 112-114.
16. Pohanka M, Kaňovský P, Bareš M, Pulkrábek J, Rektor I. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up. Eur J Neurol. 2004; 11(7): 483-488.
17. Pohanka M, Kaňovský P, Bareš M, Pulkrábek J, Rektor I. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. Park Rel Dis. 2005; 11(8): 509-512.
18. Pohanka M, Kaňovský P, Bareš M, Pulkrábek J, Rektor I. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: Results of an open, prospective, six months and one-year follow-up. Čes Slov Neurol Neurochir. 2005; 68(3): 164-168.
19. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH. et al. Association of dopamine agonist use with impulse control disorders in Parkinson's disease. Arch Neurol. 2006; 63: 969-973.
20. Weiss HD, Hirsch E, Swerigen L. et al. Impulse control disorders in Parkinson's disease patients followed in a community-based neurology practice. Mov Disord. 2008; 23: S281.
21. Isaias IU, Siri C, Cilia R, De Gaspari D, Pezzoli G. et al. The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov Disord. 2008; 23: 411-415.
22. Evans AH, Katzenschlager R, Paviour DC, O'sullivan JD, Appel S, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord. 2004; 19(4): 397-405.
23. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson's disease. Neurology. 2005; 65: 1570-1574.
24. Volkow ND, Fowler JS, Wang GJ. The addicted human brain: insights from imaging studies. J Clin Invest. 2003; 111: 1444-1451.
25. Martin-Soelch C, Missimer J, Leenders KL, Schultz W. Neural activity related to the processing of increasing monetary reward in smokers and nonsmokers. Eur J Neurosci. 2003; 18: 680-688.
26. Grace AA. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction. 2000; 95(suppl 2): s119-128.
27. Fiorillo CD, Tobler PN, Schultz W. Discrete coding of reward pobability and uncertainity by dopamine neurons. Science. 2003; 299(5614): 1898-1902.
28. Passiglione M, Seymour B, Flandin G, Dolan RJ, Firth CD. Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature. 2006; 442: 1042-1045.
29. Frank MJ, Seeberger LC, O'Reilly RC. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science. 2004; 306: 1940-1943.
30. Bechara A, Damasio AR, Damasio H, Anderson SW. Insensitivity to future consequences following damane to human prefrontal cortex. Cognition. 1994; 50: 7-15.
31. Pagonabarraga J, García-Sánchez C, Llebaria G, Pascal-Sedano B, Gironell A. et al. Controlled study of Decision-Making and cognitive impairment in Parkinson's Disease. Mov Disord. 2007; 10: 1430-1435.
32. Kobayakawa M, Koyama S, Minuta M, Kawamura M. Decision making in Parkinson's Disease: Analysis of Behavioral and Physiological Patterns in the Iowa Gambling Task. Mov Disord. 2008; 4: 547-552.
33. Thiel A, Hilker R, Kessler J, Habedank B, Herholz K. et al. Activation of basal ganglia loops in idiopathic Parkinson's disease: a PET study. J Neural Transm. 2003; 110: 1289-1301.
34. Lott DC, Kim SJ, Cook EH Jr, de Witt H. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005; 30: 602-609.
35. Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ. et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatmentof impulsive, addictive and compulsive behaviors. J Psychoactive Drugs. 2000; 32 (suppl): 1-112.
36. Kaňovský P, Kubová D, Bareš M, Hortová H, Streitová H, Znojil V, Rektor I. Suppression of L-DOPA induced dyskinesias in advanced Parkinson's disease by continuous subcutaneous infusions of apomorphine-results of one year, prospective follow-up. Čes slov Neurol Neurochir. 2002; 65/98 (1): 9-14.
37. Růžička E, Streitová H, Jech R, Kaňovský P, Roth J, Rektorová I, Mečíř P, Bareš M, Hortová H, Hejduková B, Rektor I. Amantadine-sulfate infusion in treatment of motor fluctuations ad dyskinesias in Parkinson's disease. J Neural Transm. 2000; 107: 1297-1306.
38. Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010; 68: 400-404.
39. Kashihara K, Imamura T. Amantadine may reverse punding in Parkinson's disease-observation in a patient. Mov Disord. 2008; 23: 29-130.
40. Ivanco LS, Bohnen NI. Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study. Am J Ther. 2005; 12: 467-468.
41. Sevincok L, Akoglu A, Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol. 2007; 27: 107-108.
42. Ardouin C, Voon V, Worbe Y, Abouazar N, Czernecki W. et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord. 2006; 21: 1941-1946.
43. Voon V, Potenza MN, Thomsen T. Medication-related impulse control and repetitive behaviors in Parkinson's disease. Curr Opin Neurol. 2007; 20: 484-492.